C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway

Gang Wang, Baihe Han, Ruoxi Zhang, Qi Liu, Xuedong Wang, Xingtao Huang, Dandan Liu, Weishen Qiao, Mengyue Yang, Xing Luo, Jingbo Hou, Bo YuFrontiers in Pharmacology 2021 · DOI

Abstract

Hyperglycemia-induced endothelial cell senescence is a key driver in the pathogenesis of type 2 diabetes mellitus (T2DM)-accelerated atherosclerosis. Understanding the underlying mechanisms and identifying therapeutic targets is critical for attenuating disease progression. This study investigates the protective effects of C1q/tumor necrosis factor-related protein 9 (CTRP9), a cardiokine, against hyperglycemia-induced senescence. Using human umbilical vein endothelial cells (HUVECs) and diabetic apolipoprotein E knockout (ApoE KO) mice, we demonstrate that CTRP9 activates the AMPKα pathway to suppress Krüppel-like factor 4 (KLF4). This inhibition prevents the upregulation of p21 and the downregulation of telomerase reverse transcriptase (TERT), thereby protecting endothelial cells from premature senescence and reducing atherosclerotic plaque formation in vivo.

Introduction

Patients with Type 2 diabetes face a significantly higher risk of accelerated atherosclerosis. A major contributor to this condition is "hyperglycemia-induced endothelial cell senescence." Chronic exposure to high glucose (HG) causes the endothelial cells lining blood vessels to enter a "zombie-like" state. These senescent cells stop dividing but remain metabolically active, secreting inflammatory signals (SASP) that degrade vessel walls and promote plaque growth. While CTRP9 is known to be cardioprotective, the specific molecular mechanism by which it prevents sugar-induced aging has remained unclear.

Methods

The study utilized both in vitro and in vivo models:

  • Cell Culture: HUVECs were exposed to normal glucose (NG, 5.5 mM) or high glucose (HG, 40 mM). Treatments included recombinant human CTRP9 protein, siRNAs for AMPKα and KLF4 knockdown, and the KLF4 activator APTO.
  • Animal Model: Diabetic ApoE KO mice were treated with lentiviruses overexpressing CTRP9 (Lv-CTRP9).
  • Analysis: Senescence was assessed via SA-β-gal staining. Protein expression of AMPKα, KLF4, p21, and TERT was measured using Western blotting and immunofluorescence.

Results

High Glucose Induces Endothelial Senescence and KLF4 Expression

Exposure to HG significantly increased the percentage of senescent (SA-β-gal-positive) HUVECs compared to NG or osmotic controls (D-Mannitol). This phenotypic change was accompanied by a marked increase in KLF4 and p21 protein levels, alongside a decrease in TERT expression.

Figure 1: High glucose (HG) induces endothelial cell senescence and increases KLF4 expression. (A-B) SA-β-gal staining shows increased senescence in HG-treated HUVECs. (C-I) Western blot and immunofluorescence analysis reveal upregulated KLF4 and p21, and downregulated TERT under HG conditions.

CTRP9 Protects Endothelial Cells via the AMPKα/KLF4 Axis

CTRP9 treatment was found to promote the phosphorylation of AMPKα. Activated AMPKα subsequently suppressed the HG-induced expression of KLF4. Rescue experiments confirmed this pathway: the protective effects of CTRP9 were abolished when AMPKα was knocked down or when KLF4 was artificially activated.

The Role of KLF4 in Regulating TERT

A critical finding was the "KLF4 paradox." While KLF4 has various roles, in the context of hyperglycemia, it acts as a driver of senescence. Knocking down KLF4 (siKLF4) under HG conditions restored the levels of the anti-aging enzyme TERT, whereas activating KLF4 with APTO maintained low TERT levels.

Figure 4: KLF4 mediates the suppression of TERT under high glucose conditions. Knockdown of KLF4 (siKLF4) restores TERT protein levels, while the KLF4 activator (APTO) prevents this recovery.

In Vivo Attenuation of Atherosclerosis

In diabetic ApoE KO mice, overexpression of CTRP9 via Lv-CTRP9 significantly reduced vascular senescence and the overall size of atherosclerotic plaques in the aorta. This was accompanied by a reduction in inflammatory markers (ICAM-1, IL-6, TNF-α) and a restoration of Nitric Oxide (NO) levels.

Discussion

This study identifies KLF4 upregulation as a crucial mediator of hyperglycemia-induced endothelial senescence. CTRP9 exerts its anti-atherosclerotic effects by inhibiting this process through an AMPKα/KLF4-dependent mechanism. These findings suggest that targeting the CTRP9/AMPKα/KLF4 signaling axis could offer a novel therapeutic strategy for managing accelerated atherosclerosis in diabetic patients. Future research should focus on developing stable, clinically deliverable forms of CTRP9 or small-molecule mimetics.

Summary updated

Abstract

Hyperglycemia-induced endothelial cell senescence has been widely reported to be involved in the pathogenesis of type 2 diabetes mellitus‒accelerated atherosclerosis. Thus, understanding the underlying mechanisms and identifying potential therapeutic targets for endothelial cell senescence are valuable for attenuating atherosclerosis progression. C1q/tumor necrosis factor-related protein 9 (CTRP9), an emerging potential cardiokine, exerts a significant protective effect with respect to atherosclerosis, particularly in endothelial cells. However, the exact mechanism by which CTRP9 prevents endothelial cells from hyperglycemia-induced senescence remains unclear. This study aimed to investigate the effects of CTRP9 on hyperglycemia-induced endothelial cell senescence and atherosclerotic plaque formation in diabetic apolipoprotein E knockout (ApoE KO) mice. Human umbilical vein endothelial cells (HUVECs) were cultured in normal glucose (5.5 mM) and high glucose (40 mM) with or without recombinant human CTRP9 protein (3 μg/ml) for 48 h. Purified lentiviruses overexpressing CTRP9 (Lv-CTRP9) and control vectors containing green fluorescent protein (Lv-GFP) were injected via the tail vein into streptozotocin-induced diabetic ApoE KO mice. Results revealed that exposure of HUVECs to HG significantly increased the expression of Krüppel-like factor 4 (KLF4) and cyclin-dependent kinase inhibitor p21 (p21) and decreased that of telomerase reverse transcriptase (TERT). Treatment with recombinant human CTRP9 protein protected HUVECs from HG-induced premature senescence and dysfunction. CTRP9 promoted the phosphorylation of AMP-activated kinase (AMPK), attenuated the expression of KLF4 and p21 induced by HG, and increased the expression of TERT in HUVECs. Furthermore, in the background of AMPKα knockdown or KLF4 activation, the protective effects of CTRP9 were abolished. <i>In-vivo</i> experiments showed that the overexpression of CTRP9 inhibited vascular senescence and reduced atherosclerotic plaque formation in ApoE KO mice with diabetes<b>.</b> In conclusion, we demonstrate that KLF4 upregulation plays a crucial role in HG-induced endothelial senescence. This anti-atherosclerotic effect of CTRP9 may be partly attributed to the inhibition of HG-induced endothelial senescence through an AMPKα/KLF4-dependent mechanism, suggesting that CTRP9 could benefit further therapeutic approaches for type 2 diabetes mellitus‒accelerated atherosclerosis.
BibTeX
@inproceedings{wang2021c,
  author = {Gang Wang and Baihe Han and Ruoxi Zhang and Qi Liu and Xuedong Wang and Xingtao Huang and Dandan Liu and Weishen Qiao and Mengyue Yang and Xing Luo and Jingbo Hou and Bo Yu},
  title = {{C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.758792},
}
Figure